New weight-loss shot appears to outperform other obesity drugs on market
Eli Lilly says participants in a sizable trial of retatrutide lost much more weight compared to other weight-loss drugs
A new weight-loss drug has helped participants in a sizable trial lose much more weight than other obesity drugs already on the market – up to an average of 28% of their body weight – Eli Lilly https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html">announced Thursday.
The Indiana-based pharmaceutical company in a press statement said that retatrutide, a once-weekly triple hormone receptor agonist, led to an average weight loss of 70.3lbs (28.3%) over 80 weeks among participants receiving the 12mg dose, with 45.3% achieving at least 30% weight loss.
https://www.theguardian.com/science/2026/may/21/weight-loss-shot-eli-lilly-glp-1">Continue reading...Lilly weight loss drug results
- New Eli Lilly weight loss drug has dramatic effects in clinical trial Washington Examiner —
- Eli Lilly’s next-gen obesity drug beats Ozempic and Mounjaro, helps patients lose over 30% body weight in trial The Indian Express —
- Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight - Reuters Reuters —
- A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says Time —
- Eli Lilly: Next-gen weight loss drug may be more effective than others UPI —